Evoke Pharma, Inc. (NASDAQ:EVOK) Sees Large Decline in Short Interest

Evoke Pharma, Inc. (NASDAQ:EVOK) was the target of a significant decline in short interest in July. As of July 31st, there was short interest totalling 2,100 shares, a decline of 78.6% from the July 15th total of 9,800 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average trading volume of 3,500 shares, the days-to-cover ratio is presently 0.6 days.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Evoke Pharma in a research note on Thursday, August 8th. They issued a “sell” rating on the stock.

Evoke Pharma Stock Up 0.9 %

Shares of NASDAQ:EVOK traded up $0.05 during trading on Tuesday, hitting $5.74. 1,789 shares of the company traded hands, compared to its average volume of 3,885. The stock has a market capitalization of $49.35 million, a price-to-earnings ratio of -3.14 and a beta of 0.38. The business’s fifty day moving average is $6.16 and its 200-day moving average is $6.59. Evoke Pharma has a one year low of $4.32 and a one year high of $18.60.

Evoke Pharma (NASDAQ:EVOK) last posted its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($2.04) EPS for the quarter. The company had revenue of $1.74 million for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.